Understanding and Tackling the Placebo Response in Parkinson’s Disease
For indications like Parkinson’s disease (PD) that rely on subjective reporting measures, the placebo response is a major problem:
A problem that snowballs into higher development costs, longer timelines and the premature abandonment of development programs.
And, ultimately, a lack of cure for patients with PD.
In this guide, we discuss:
- How the placebo problem uniquely plays out in PD patients
- Historical approaches to managing the placebo response in PD
- A new strategy to work towards successfully delivering a cure
Download the guide to dig in.
Download our guide
Cognivia is an innovator of analytical tools to optimize and accelerate the clinical development of new medicines. The privately held company was founded in 2013 by longtime colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace. Cognivia helps lessen risk and increase clinical trial success. It can help reduce the variability of study data by 30 percent, which directly translates into increased study power and reduced risk of trial failure. This can further lead to fewer patients needed in a study, equating to less cost and time.
The company offers Placebell, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.